A Precision Medicine Company
Working to identify the root cause of multiple neurologic, psychiatric, and behavioral disorders.

The Cunningham Panel is an aid to a physician’s diagnosis of an infection-triggered autoimmune neuropsychiatric disorder.

Revolutionizing the way we look at mental disorders

Leaders in autoimmunity testing for neuropsychiatric illnesses

The Cunningham Panel™ helps clinicians identify whether a patient’s neurologic and/or psychiatric symptoms may be due to an infection-triggered basal ganglia encephalitis (BGE), which includes autoimmune neuropsychiatric syndromes such as PANS/PANDAS. Symptoms of BGE can mimic various mental illnesses.
The Cunningham Panel measures circulating levels of autoantibodies attacking brain receptors, as well as autoantibodies that stimulate the production of neurotransmitters in the basal ganglia. These interactions have the potential to disrupt neuronal functioning and can impact movement, behavior and cognition.
Check with your doctor as elevated levels of certain autoantibodies may indicate that neuropsychiatric symptoms could be due to BGE (a type of autoimmune encephalitis) rather than a primary psychiatric disorder.
The Cunningham Panel™ measures antibodies attacking the brain causing inflammation and abnormal behaviors

Mental illness, behavioral disorder, or autoimmune encephalitis?

Common infections (i.e., strep, influenza, mycoplasma, Lyme disease, Babesia, Bartonella and coxsackie virus) can trigger autoimmune basal ganglia encephalitis. This condition can cause neurologic, behavioral and psychiatric symptoms which may include OCD, tics, anxiety, depression, and behaviors associated with autism spectrum disorders.

Science That Impacts Lives.

There is a growing body of scientific evidence documenting the connection between infection, inflammation, immune dysfunction and the development of neurologic and psychiatric illnesses. Following is a list of peer-reviewed journal articles by world-renowned researchers and clinicians investigating infection-induced autoimmune neurologic disorders.

Physicians worldwide are using the Cunningham Panel™ to help guide diagnosis and target treatments.

  • Moleculera Labs: Our Mission
    Dr. Craig Shimasaki, president and CEO of Moleculera Labs, discusses the company’s mission to develop and offer advanced testing services that will help clinicians identify autoimmune-induced neuropsychiatric conditions.
  • Autoimmunity testing with the Cunningham Panel™
    Dr. Madeleine Cunningham explains how the Cunningham Panel™ can assist in determining whether an autoimmune process may be causing a person’s neurologic and/or psychiatric symptoms.
  • testimonial Wendy
    “My son began having symptoms of ADHD and autism. He had severe social anxiety and fits of rage. The doctors didn’t have an answer. He had a history of strep infections and eventually a psychiatrist suspected he had PANDAS. The Cunningham Panel™ test results confirmed the diagnosis and helped the doctor develop a treatment plan. The test gave us piece of mind that we finally had the right answer.”
    The Cunningham Panel™ can help identify the level of autoimmune antibodies associated with Neuropsychiatric Disorders
  • testimonial Martha
    “I am so thankful to have had the Cunningham Panel™ to confirm my daughter’s PANDAS diagnosis. Your nurse hit the nail on the head when she pointed out that one of her high markers can be associated with anger. That is the first thing we notice when she begins to flare, and no one else ever made this connection. We are so appreciative to have quantifiable results because we second-guessed ourselves so many times, and now we know it's not just our imagination, bad parenting or some kind of hidden psychiatric illness. Thank you so much for giving us hope!”
    The Cunningham Panel™ can help identify the level of autoimmune antibodies associated with Neuropsychiatric Disorders
  • testimonial Lori
    “We had the Cunningham Panel™ test done on my daughter. She had OCD, separation anxiety and tics but also a lot of physical discomfort from joint pain and muscle aches. She was in treatment but never got completely well. The test results confirmed she had an autoimmune problem. I am so grateful we had a test that could help us figure out the diagnosis and determine the best treatment plan.”
    The Cunningham Panel™ can help identify the level of autoimmune antibodies associated with Neuropsychiatric Disorders

Remarkable results happen here.

Infection-triggered autoimmune disorders, such as PANS/PANDAS, which cause neuropsychiatric symptoms can be difficult to recognize. The following videos provide insight into the complexity of these disorders and demonstrate how the Cunningham Panel™ can assist physicians.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.